Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees

BMC Cardiovascular Disorders

Volumn 10, Issue , 2010, Pages

  Chapman, Richard H ^a   Yeaw, Jason ^a   Roberts, Craig S ^b  

^a IQVIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; AMLODIPINE; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGE; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH INSURANCE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; UNITED STATES; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY;

AMLODIPINE; ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PYRROLES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 77953562079     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-10-29     Document Type: Article

References (35)

1. World Health Organization Cardiovascular diseases (CVDs). Fact sheet number 317. Updated September 2009. World Health Organization., http://www.who.int/mediacentre/factsheets/fs317/en/index.html
2. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992, 152:56-64. 10.1001/archinte.152.1.56, 1728930.
3. Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002, 23:528-535. 10.1053/euhj.2001.2888, 11922642.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. 10.1001/jama.288.23.2981, 12479763, ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
5. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S, Kristinsson A, McInnes G. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158. 10.1016/S0140-6736(03)12948-0, 12686036.
6. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman M, Weiss N. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003, 289:2534-2544. 10.1001/jama.289.19.2534, 12759325.
7. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346. 10.1001/jama.282.24.2340, 10612322.
8. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004, 35:2902-2909. 10.1161/01.STR.0000147965.52712.fa, 15514180.
9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, . Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. (Erratum in: Lancet 2005;366(9494):1358; Lancet 2008;371(9630):2084), 10.1016/S0140-6736(05)67394-1, 16214597, Cholesterol Treatment Trialists' (CTT) Collaborators.
10. Patel BV, Leslie RS, Thiebaud P, Nichol MB, Tang ST, Solomon H, Honda D, Foody JM. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008, 4:673-681. 2515427, 18827917.
11. Chapman RH, Pelletier EM, Smith PJ, Roberts CS. Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?. Patient Preference Adherence 2009, 3:265-275.
12. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005, 165:1147-1152. 10.1001/archinte.165.10.1147, 15911728.
13. Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging 2008, 25:885-892. 10.2165/00002512-200825100-00008, 18808213.
14. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10-17. 10.1161/01.HYP.0000103630.72812.10, 14638619.
15. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000, 9(9 Suppl):2-6.
16. Julius S, Cohn JN, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Lagast H. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens 2004, 6:10-17.
17. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005, 62:1468-1475. 10.2146/ajhp040419, 15998926.
18. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007, 298:61-69. 10.1001/jama.298.1.61, 17609491.
19. Taira N. Nifedipine: a novel vasodilator. Drugs 2006, 66:1-3. Erratum in: Drugs 2007;67(13):1849, 10.2165/00003495-200666991-00002, 18203343.
20. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008, 7:717-725. 10.1517/14740330802396984, 18983218.
21. Bouchard MH, Dragomir A, Blais L, Bérard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. J Clin Pharmacol 2007, 63:698-708.
22. Perreault S, Dragomir A, Roy L, White M, Blais L, Lalonde L, Bérard A. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010, 69:74-84. 10.1111/j.1365-2125.2009.03547.x, 20078615.
23. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009, 120:1598-605. 10.1161/CIRCULATIONAHA.108.830299, 19805653.
24. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10:3-12. 10.1111/j.1524-4733.2006.00139.x, 17261111.
25. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
26. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006, 166:1836-1841. 10.1001/archinte.166.17.1836, 17000939.
27. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008, 155:772-779. 10.1016/j.ahj.2007.12.011, 18371492.
28. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm 2009, 66:1471-1477. 10.2146/ajhp080238, 19667004.
29. Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med 2008, 25:850-855. 10.1111/j.1464-5491.2008.02476.x, 18644071.
30. LaFleur J, Thompson CJ, Joish VN, Charland SL, Oderda GM, Brixner DI. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006, 40:1274-1279. 10.1345/aph.1G646, 16849622.
31. Jackson KC, Sheng X, Nelson RE, Keskinaslan A, Brixner DI. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008, 30:1558-1563. 10.1016/j.clinthera.2008.08.010, 18803997.
32. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007, 64:1279-1283. 10.2146/ajhp060434, 17563050.
33. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed 2007, 9:58. 2100116, 18092064.
34. Sever PS, Poulter NR, Mastorantonakis S, Chang C, Dahlof B, Wedel H. Coronary heart disease benefits from blood pressure and lipid-lowering. Int J Cardiol 2009, 135:218-222. 10.1016/j.ijcard.2009.01.036, 19232755.
35. Sever PS, Poulter NR, Dahlof B, Wedel H, . ASCOT Investigators Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens 2009, 27:947-54. 10.1097/HJH.0b013e328326cb1a, 19318984, ASCOT Investigators.